Why the study?
The inflammatory response in ischemic myocardium determines remodeling and functional deterioration, with neutrophil-derived myeloperoxidase acting as a key mediator, prompting investigation into whether neutrophil reduction or myeloperoxidase inhibition is protective.
Does neutrophil reduction, myeloperoxidase deficiency, or myeloperoxidase inhibition improve cardiac function and reduce structural remodeling in murine models of myocardial infarction?
Population
Two murine models of MI
Comparison
PMN reduction, MPO deficiency, and oral MPO inhibitor AZM198
Design
Preclinical animal study
Authors
Loading...
MPO-targeted therapies merit exploration in post-MI remodeling; leaves open need for clinical validation.
Does neutrophil reduction, myeloperoxidase deficiency, or myeloperoxidase inhibition improve cardiac function and reduce structural remodeling in murine models of myocardial infarction?
Inhibition of myeloperoxidase or reduction of neutrophils improves left ventricular function and reduces adverse remodeling in murine models of myocardial infarction, suggesting a potential therapeutic target.
Guthoff et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: